PARP inhibitor
May 29, 2026
Cracks in the mCRPC Treatment Market: 8 Companies at Risk of Falling Behind
Summary The mCRPC market, valued at around USD 8 billion in 2025, is undergoing rapid disruption driven by scientific innovation, patent expirations, and shifting treatment paradigms. Once dominated by blockbuster androgen receptor inhibitors like ZYTIGA and XTANDI, the landscape is now fragmenting under pre...
Read More...
Apr 27, 2017
Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A
Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
